Clinical Trial

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Study acronym: CONSTANCE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Trial Details
NCT Number NCT06795048
Lead Sponsor Hoffmann-La Roche
Conditions Neovascular Age-related Macular Degeneration (nAMD)
Enrollment 274 participants
Start Date 2025-03-14
Primary Completion 2026-10-15 (estimated)
Study Completion 2027-09-16 (estimated)
Updated on ClinicalTrials.gov 2026-04-30